Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...